OLMA News and Press, Olema Pharmaceuticals Inc. From 01/26/24

2024-01-26 16:59:28 ET Gainers: Olema Pharmaceuticals ( OLMA ) +3% . Baijiayun Group  ( RTC ) +3% . Cipher Mining ( CIFR ) +2% . Evolus,  ( EOLS ) +2% . SSR Mining  ( SSRM ) +2% . Losers: Progress Software ...

2024-01-17 17:06:02 ET Gainers: Hertz Global Holdings ( HTZ ) +6% . GrabTaxi Holdings ( GRAB ) +4% . R1 RCM ( RCM ) +4% . Arhaus ( ARHS ) +3% . MacroGenics ( MGNX ) +2% . Losers: Adagene ( ADAG ) -8% . biote (...

OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer models Initiating IND-enabling studies with goal to advance into clinical development by end of 2024 SAN FRANCISCO, Jan. 08, 2024 ...

2024-01-03 08:29:38 ET Summary OLMA presented data last month, and the stock went down a little but now has recovered. The data needs to be compared with other approved oral SERDs, specifically with elacestrant. However, such a comparison is not possible, so we need to wait fo...

SAN FRANCISCO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s ...

2023-12-21 01:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-05 13:28:55 ET More on Olema Pharmaceuticals Olema Pharmaceuticals: Advancing On Multiple Fronts Olema: Two-Pronged Approach To Treat Breast Cancer Patients Olema Pharmaceuticals officer discloses sale of about 10K shares Seeking Alpha’s Quant ...

Palazestrant (OP-1250) in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile consistent with the FDA-approved labels of ribociclib or palbociclib plus an endocrine therapy ...

Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with palbociclib, and the OPERA-01 Phase 3 clinical trial in progress will be presented on Dec. 7, 2023 ...

Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.22% on the day to $13.25. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapie...